Alzheimer's & Dementia·19 AugExperience with donanemab over a 1-year period: observations of side effects and compliance from a regional specialty medical centerStudy in peopleInterventionsPaper
AAIC 2025 Abstract·26 DecThe Real World Experience with Lecanemab: A US Case StudyStudy in peopleInterventionsPaper